Columnist Jennifer Lynne assesses the effects of Pfizer's decision to halt production of its hemophilia B gene therapy, Beqvez.

Pfizer said it will discontinue gene therapy Beqvez (fidanacogene elaparvovec-dzkt), an approved hemophilia B treatment.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Scientists compared five families and multiple generations to find a gene variant that prevents COPA Syndrome and opens the door to a new gene therapy for the condition.

A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...

A vast search of natural diversity has led scientists at MIT's McGovern Institute and the Broad Institute of MIT and Harvard ...

The "43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025" report has been added to ResearchAndMarkets.com's offering.The 43rd Annual JP Morgan Healthcare Conference took place in San ...

Red blood cells carry oxygen from the lungs to every other organ, and blood-forming stem cells must make about 200 billion ...

My brothers and I compare our genetic analyses and what diseases we are genetically at risk for and what conditions we ...